© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 25, 2021
Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.
An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.
Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.
Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.
An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.
Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.